Back to top

Analyst Blog

Johnson & Johnson (JNJ - Analyst Report) will be selling its Ortho-Clinical Diagnostics business to The Carlyle Group for about $4 billion. The company said that it has accepted the binding offer from The Carlyle Group which was announced on Jan 16.

Johnson & Johnson said that it expects the deal to go through in mid-14. We expect updates on the deal on Apr 15 when the company announces its first quarter results.

The upcoming sale of the Ortho Clinical Diagnostics business indicates Johnson & Johnson’s increased focus on the pharma business which has been performing well. Johnson & Johnson reported pharmaceutical sales of $28.1 billion in 2013, up 10.9%.

Although some products in the pharma segment are facing generic competition, new products are steadily gaining traction and performing well. Some of the important and promising new products in Johnson & Johnson’s portfolio include Zytiga, Invokana, Stelara, Xarelto, Simponi and Invega Sustenna. Other growth drivers include Prezista, Remicade and Velcade. We believe prostate cancer treatment, Zytiga, which posted sales of $1.7 billion in 2013, has multi-billion dollar potential.

Another product with blockbuster potential is Imbruvica. Imbruvica is approved for mantle cell lymphoma and chronic lymphocytic leukemia in patients who have received at least one prior treatment.

We note that quite a few companies have been selling off non-core business segments with the intention of creating value and focusing on core areas. A case in point is Pfizer (PFE - Analyst Report) which divested its Nutrition business, sold its Capsugel unit and spun off its Animal Health segment.

Both Johnson & Johnson and Pfizer are Zacks Rank #3 (Hold) stocks. Some better-ranked stocks in the pharma sector include Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) and Shire plc (SHPG - Analyst Report). Both are Zacks Rank #1 (Strong Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%